Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Curon Biopharmaceutical (Shanghai) Co. Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is assigned to 1 distinct examiner and 1 distinct art unit. The presence of only a single pending matter indicates a highly concentrated prosecution phase for the company. For practitioners, this means the immediate success of the portfolio in the Biotechnology & Pharmaceuticals sector depends entirely on the outcome of this specific case.
OUSPENSKI, ILIA I is the busiest examiner, managing 1 busiest examiner pending action. Because this 1 busiest examiner pending action is the only one currently active, the prosecution strategy is entirely dependent on the interaction with this individual. There are no other 1 distinct examiners to provide a baseline for comparison or alternative results within the current workload. The strategy must be tailored specifically to the preferences of this one official.
The 1 distinct art unit involved shows a specific technical focus for the current filing. With only 1 pending office action, the company's immediate patent outcomes are tied to the results of this single case. Practitioners must focus all efforts on this 1 distinct examiner to advance the company's intellectual property goals. This lack of diversity in the 1 distinct art unit means there are no other active paths to allowance at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18706348 | NOVEL ANTI-L1CAM ANTIBODY | OUSPENSKI, ILIA I | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18706348 | NOVEL ANTI-L1CAM ANTIBODY | OUSPENSKI, ILIA I | 1644 | §112DP | Non-Final OA | — | Pending | Apr 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCuron Biopharmaceutical (Shanghai) Co. Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ilia I Ouspenski has the most, with 1 of Curon Biopharmaceutical (Shanghai) Co. Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.